{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:52:42Z","timestamp":1789080762946,"version":"build-2803163510"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T00:00:00Z","timestamp":1751932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06255-1","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:13:42Z","timestamp":1752138822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Relationship between programmed cell death ligand 1 expression and the number of biopsy specimens in advanced gastric cancer"],"prefix":"10.1007","volume":"151","author":[{"given":"Taro","family":"Mizuno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiya","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunobu","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Sakakida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Masuishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroya","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigenori","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Tajika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,8]]},"reference":[{"issue":"9742","key":"6255_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687\u2013697. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X","journal-title":"Lancet"},{"issue":"4","key":"6255_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","volume":"35","author":"AN Bartley","year":"2017","unstructured":"Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S et al (2017) HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol 35(4):446\u2013464. https:\/\/doi.org\/10.1200\/JCO.2016.69.4836","journal-title":"J Clin Oncol"},{"issue":"3","key":"6255_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"issue":"10294","key":"6255_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398(10294):27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"},{"issue":"6","key":"6255_CR5","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.ejca.2012.10.018","volume":"49","author":"HE Lee","year":"2013","unstructured":"Lee HE, Park KU, Yoo SB, Nam SK, Park DJ, Kim H-H, Lee HS (2013) Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer 49(6):1448\u20131457. https:\/\/doi.org\/10.1016\/j.ejca.2012.10.018","journal-title":"Eur J Cancer"},{"issue":"7","key":"6255_CR6","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.3390\/jcm12072636","volume":"12","author":"Y Narita","year":"2023","unstructured":"Narita Y, Muro K (2023) Updated immunotherapy for gastric cancer. J Clin Med 12(7):2636. https:\/\/doi.org\/10.3390\/jcm12072636","journal-title":"J Clin Med"},{"issue":"11","key":"6255_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK et al (2023) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 24(11):1181\u20131195. https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6","journal-title":"Lancet Oncol"},{"issue":"5","key":"6255_CR8","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s10120-021-01195-4","volume":"24","author":"B Schoemig-Markiefka","year":"2021","unstructured":"Schoemig-Markiefka B, Eschbach J, Scheel AH, Pamuk A, Rueschoff J, Zander T, Buettner R, Schroeder W, Bruns CJ, Loeser H et al (2021) Optimized PD-L1 scoring of gastric cancer. Gastric Cancer 24(5):1115\u20131122. https:\/\/doi.org\/10.1007\/s10120-021-01195-4","journal-title":"Gastric Cancer"},{"issue":"10389","key":"6255_CR9","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","volume":"401","author":"K Shitara","year":"2023","unstructured":"Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J et al (2023) Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet 401(10389):1655\u20131668. https:\/\/doi.org\/10.1016\/S0140-6736(23)00620-7","journal-title":"Lancet"},{"issue":"2","key":"6255_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10120-015-0502-3","volume":"19","author":"N Tominaga","year":"2016","unstructured":"Tominaga N, Gotoda T, Hara M, Hale MD, Tsuchiya T, Matsubayashi J, Kono S, Kusano C, Itoi T, Fujimoto K et al (2016) Five biopsy specimens from the proximal part of the tumor reliably determine HER2 protein expression status in gastric cancer. Gastric Cancer 19(2):553\u2013560. https:\/\/doi.org\/10.1007\/s10120-015-0502-3","journal-title":"Gastric Cancer"},{"issue":"3","key":"6255_CR11","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","volume":"18","author":"E Van Cutsem","year":"2015","unstructured":"Van Cutsem E, Bang Y-J, Feng-yi F, Xu JM, Lee K-W, Jiao S-C, Chong JL, L\u00f3pez-Sanchez RI, Price T, Gladkov O et al (2015) HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer 18(3):476\u2013484. https:\/\/doi.org\/10.1007\/s10120-014-0402-y","journal-title":"Gastric Cancer"},{"issue":"3","key":"6255_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41416-019-0515-5","volume":"121","author":"K Yamashita","year":"2019","unstructured":"Yamashita K, Iwatsuki M, Harada K, Koga Y, Kiyozumi Y, Eto K, Hiyoshi Y, Ishimoto T, Iwagami S, Baba Y et al (2019) Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer? Br J Cancer 121(3):278\u2013280. https:\/\/doi.org\/10.1038\/s41416-019-0515-5","journal-title":"Br J Cancer"},{"key":"6255_CR13","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12935-020-01273-0","volume":"20","author":"M Ye","year":"2020","unstructured":"Ye M, Huang D, Zhang Q, Weng W, Tan C, Qin G, Jiang W, Sheng W, Wang L (2020) Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections. Cancer Cell Int 20:186. https:\/\/doi.org\/10.1186\/s12935-020-01273-0","journal-title":"Cancer Cell Int"},{"issue":"24","key":"6255_CR14","doi-asserted-by":"publisher","first-page":"6453","DOI":"10.1158\/1078-0432.CCR-20-2085","volume":"26","author":"KI Zhou","year":"2020","unstructured":"Zhou KI, Peterson B, Serritella A, Thomas J, Reizine N, Moya S, Tan C, Wang Y, Catenacci DVT (2020) Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin Cancer Res 26(24):6453\u20136463. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2085","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06255-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06255-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06255-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:13:42Z","timestamp":1752138822000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06255-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":14,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["6255"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06255-1","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,8]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T Mizuno: honoraria for lectures from Astellas and Merck BioPharma. Y Narita: research funding to my institution from Chugai, MSD, Amgen, ONO Pharmaceutical, Astellas, Sanofi, Taiho, Eisai, Daiichi Sankyo, Novartis, and Pfizer; honoraria for lectures, presentations, and speaker bureaus from Yakult Honsha, Taiho, Eli Lilly, Daiichi Sankyo, ONO Pharmaceutical, and Bristol-Meyers Squibb; and participation in the Advisory Board of Daiichi Sankyo. T Masuishi: research funding to my institution from MSD, Daiichi Sankyo, ONO Pharmaceutical, Novartis, Amgen, Syneos Healthe Clinical, Boehringer-Ingelheim, Pfizer, Cimic Shift Zero, Eli Lilly, Abbvie, and Merck BioPharma; honoraria for lectures, presentations, and speaker bureaus from Takeda, Chugai, Merck BioPharma, Taiho, Bayer, Lilly Japan, Yakult Honsha, Sanofi, Daiichi Sankyo, Ono Pharmaceutical, Bristol-Meyers Squibb, Nippon Kayaku, MSD, Takata, Guardant Health, and Amgen. H Taniguchi: research funding to my institution from Daiichi Sankyo; honoraria for lectures from Ono Pharmaceutical, Taiho, and Takeda. S Kadowaki: research funding to my institution from Ono Pharmaceutical, MSD, Janssen Pharmaceutical, Eli Lilly, Daiichi Sankyo, AstraZeneca, Astellas, Taiho, Nobel Pharmaceutical, Bayer, Chugai, Abbvie, Kyowa Kirin, and Novartis; honoraria for lectures, presentations, and speaker bureaus from Ono Pharmaceutical, MSD, Merck KgaA, Eli Lilly, Bayer, Novartis, Taiho, Daiichi Sankyo, Bristol-Meyers Squibb, Chugai, and Eisai. M Ando: honoraria for lectures, presentations, and speaker bureaus from Eisai, Chugai, Ono Pharmaceutical, and Taiho. M Tajika: honoraria for educational events form Bristol-Meyers Squib and EA Pharma. K Muro: research funding to my institution from Amgen, Taiho, PRA Health Sciences, Chugai, and MSD; consulting fees from Amgen, AstraZeneca, Ono Pharmaceutical, Astellas, and Chugai; honoraria for lectures from Ono Pharmaceutical, Taiho, Bristol-Meyers Squibb, Eli Lilly, MSD, Takeda, and Daiichi Sankyo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of Aichi Cancer Center Hospital (Reference Number: 2024-0-515).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The requirement for individualized informed consent was waived because of the retrospective nature of the study. A committee-approved information disclosure document has been published on the hospital\u2019s website.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"206"}}